Penbrook Management LLC increased its stake in shares of Cryoport, Inc. (NASDAQ:CYRX – Free Report) by 6.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,570 shares of the company’s stock after buying an additional 2,975 shares during the period. Penbrook Management LLC’s holdings in Cryoport were worth $409,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in CYRX. Fred Alger Management LLC boosted its position in shares of Cryoport by 49.9% during the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after buying an additional 898,481 shares during the period. Thematics Asset Management lifted its stake in Cryoport by 176.2% during the 3rd quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after acquiring an additional 1,087,800 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Cryoport by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock valued at $8,902,000 after acquiring an additional 38,520 shares during the period. State Street Corp grew its position in Cryoport by 2.8% in the 3rd quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after acquiring an additional 27,438 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Cryoport during the third quarter worth about $3,405,000. Institutional investors and hedge funds own 92.90% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently commented on CYRX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Friday, January 17th. UBS Group raised their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, October 18th. Guggenheim started coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Roth Mkm decreased their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.29.
Insider Transactions at Cryoport
In other Cryoport news, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total value of $339,000.00. Following the transaction, the chief executive officer now directly owns 712,747 shares in the company, valued at $4,832,424.66. This represents a 6.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares of the company’s stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,869 shares of company stock valued at $735,673. Corporate insiders own 10.10% of the company’s stock.
Cryoport Price Performance
Shares of CYRX opened at $7.85 on Thursday. The firm’s fifty day simple moving average is $7.81 and its 200-day simple moving average is $7.96. Cryoport, Inc. has a twelve month low of $5.32 and a twelve month high of $20.10. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.
Cryoport (NASDAQ:CYRX – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.23. The company had revenue of $56.66 million for the quarter, compared to analysts’ expectations of $58.13 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period last year, the firm earned ($0.31) earnings per share. As a group, equities research analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Articles
- Five stocks we like better than Cryoport
- The 3 Best Blue-Chip Stocks to Buy Now
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- What Investors Need to Know About Upcoming IPOs
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc. (NASDAQ:CYRX – Free Report).
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.